Last10K.com

Athenex, Inc. (ATNX) SEC Filing 10-K Annual report for the fiscal year ending Sunday, December 31, 2017

Athenex, Inc.

HISTORY TOOLS
CIK: 1300699 Ticker: ATNX

Exhibit 99.1

Athenex, Inc. Announces Fourth Quarter and Full-Year 2017 Results

 

 

Fourth Quarter 2017 and Recent Business Highlights:

 

  •   Met enrollment targets and received positive feedback from the US FDA for Oraxol Phase III Clinical Trial in metastatic breast cancer

 

  •   Announced strategic partnership with Almirall for KX2-391 Ointment for the treatment of actinic keratosis

 

  •   Received a Promising Innovative Medicine (PIM) designation for Oraxol by the UK Medicines and Healthcare Products Regulatory Agency

 

  •   Completed patient enrollment for both Phase III clinical studies of KX2-391 Ointment for actinic keratosis indications months ahead of schedule

 

  •   Launched 7 new products, including Epinephrine, Norepinephrine, Caspofungin Acetate Injection, Doxorubicin, Etomidate Injection, Gemcitabine Injection and Paclitaxel Injection in the Athenex Pharmaceutical Division, further expanding the APD product portfolio

 

  •   Announced secondary stock offering raising approximately $68 million in capital

 

  •   Revenue of $14.9 million for the fourth quarter 2017, up $9.7 million year-over-year

 

  •   Full-year revenue of $38.0 million, up 85% year-over-year

 

  •   Initiates full-year 2018 revenue guidance to the range of $100 million - $125 million

BUFFALO, N.Y., March 26, 2018 — Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced its financial results and business highlights for the fourth quarter and full year 2017.

Dr. Johnson Lau, Athenex’s Chief Executive Officer, stated, “I am pleased to report Athenex delivered a strong finish to our first year as a publicly traded company. We continued to make significant progress with our Phase III Clinical Trials for Oraxol in metastatic breast cancer and KX2-391 Ointment for actinic keratosis, allowing us to meet the enrollment targets in February 2018. During the fourth quarter, we also received a Promising Innovative Medicine designation from the United Kingdom MHRA for Oraxol, based on early clinical data. Additionally, we announced our strategic partnership with Almirall, a leading skin-health focused global pharmaceutical company, marking an important step in the development and commercialization of KX2-391 Ointment.”

Dr. Lau continued, “Our impressive clinical progress and commercial efforts in 2017 generated solid momentum that has continued into 2018. We are delighted with the positive feedback from the FDA on the Phase III Clinical Study design for Oraxol, which provides further validation of our regulatory pathway for Oraxol. The rapid patient recruitment rates for our KX2-391 Ointment Phase III clinical trials underscores the excitement of the clinical and scientific communities for this new treatment. Finally, our commercial platform continues to be a differentiating strength of our business model, driving record revenues to support our clinical program while building the infrastructure that can support the global commercialization of our proprietary products. We are well positioned to capitalize on our growth opportunities and look forward to creating value for our shareholders.”

The following information was filed by Athenex, Inc. (ATNX) on Monday, March 26, 2018 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Athenex, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Athenex, Inc..

Continue

Assess how Athenex, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Athenex, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2018 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Document And Entity Information
Consolidated Balance Sheets
Consolidated Balance Sheets (parenthetical)
Consolidated Statements Of Cash Flows
Consolidated Statements Of Operations And Comprehensive Loss
Consolidated Statements Of Stockholders Equity
Consolidated Statements Of Stockholders Equity (parenthetical)
Accrued Expenses
Accrued Expenses (detail)
Accrued Expenses (tables)
Accumulated Other Comprehensive Income (loss)
Accumulated Other Comprehensive Income (loss) (tables)
Accumulated Other Comprehensive Income (loss) - Schedule Of Accumulated Other Comprehensive Income (loss) (detail)
Business Acquisitions
Business Acquisitions (tables)
Business Acquisitions - Additional Information (detail)
Business Acquisitions - Pro Forma Information (detail)
Business Acquisitions - Summary Of Fair Values Of Assets And Liabilities Acquired (detail)
Business Acquisitions - Summary Of Fair Values Of Assets And Liabilities Acquired (parenthetical) (detail)
Business And Economic Collaborative Agreements
Business And Economic Collaborative Agreements - Additional Information (detail)
Business Segment, Geographic, And Concentration Risk Information
Business Segment, Geographic, And Concentration Risk Information (tables)
Business Segment, Geographic, And Concentration Risk Information - Additional Information (detail)
Business Segment, Geographic, And Concentration Risk Information - Summary Of Customer Revenue And Accounts Receivable Concentration (detail)
Business Segment, Geographic, And Concentration Risk Information - Summary Of Depreciation, Amortization And Assets By Segment (detail)
Business Segment, Geographic, And Concentration Risk Information - Summary Of Property And Equipment By Geographical Segment (detail)
Business Segment, Geographic, And Concentration Risk Information - Summary Of Revenue By Geographical Segment (detail)
Business Segment, Geographic, And Concentration Risk Information - Summary Of Revenue By Product Group (detail)
Business Segment, Geographic, And Concentration Risk Information - Summary Of Revenue By Segments (detail)
Business Segment, Geographic, And Concentration Risk Information - Summary Of Segment Information (detail)
Commitments And Contingencies
Commitments And Contingencies (tables)
Commitments And Contingencies - Additional Information (detail)
Commitments And Contingencies - Schedule Of Future Minimum Payments Under Non-cancelable Leases (detail)
Company And Nature Of Business
Company And Nature Of Business - Additional Information (detail)
Contingent Consideration
Contingent Consideration (tables)
Contingent Consideration - Additional Information (detail)
Contingent Consideration - Schedule Of Reconciliation Of Contingent Consideration Liability (detail)
Debt
Debt (tables)
Debt - Additional Information (detail)
Debt - Summary Of Balances Of Debt (detail)
Debt - Summary Of Balances Of Debt (parenthetical) (detail)
Deferred Compensation
Deferred Compensation - Additional Information (detail)
Fair Value Measurements
Fair Value Measurements (tables)
Fair Value Measurements - Additional Information (detail)
Fair Value Measurements - Schedule Of Assets And Liabilities Measured At Fair Value On A Recurring Basis (detail)
Fair Value Measurements - Summary Of Changes In Fair Value Of Company's Level 3 Financial Instruments (detail)
Goodwill And Intangible Assets, Net
Goodwill And Intangible Assets, Net (tables)
Goodwill And Intangible Assets, Net - Additional Information (detail)
Goodwill And Intangible Assets, Net - Goodwill (detail)
Goodwill And Intangible Assets, Net - Schedule Of Expected Amortization Expense Of Finite Lived Intangible Expense (detail)
Goodwill And Intangible Assets, Net - Summary Of Identifiable Intangible Asset, Net (detail)
Income Taxes
Income Taxes (tables)
Income Taxes - Additional Information (detail)
Income Taxes - Components Of Loss Before Income Tax Expense (benefit) (detail)
Income Taxes - Components Of The Income Tax Expense (benefit) (detail)
Income Taxes - Schedule Of Deferred Tax Assets (liabilities) (detail)
Income Taxes - Schedule Of Income Tax Expense (benefit) Differs From The Federal Statutory Rate (detail)
Inventories
Inventories (tables)
Inventories - Schedule Of Inventories (detail)
Net Loss Per Share Attributable To Athenex, Inc. Common Stockholders
Net Loss Per Share Attributable To Athenex, Inc. Common Stockholders (tables)
Net Loss Per Share Attributable To Athenex, Inc. Common Stockholders - Schedule Outstanding Shares Of Common Stock Equivalents Excluded From The Calculation Of Diluted Net Loss Per Share (detail)
Property And Equipment, Net
Property And Equipment, Net (tables)
Property And Equipment, Net - Additional Information (detail)
Property And Equipment, Net - Schedule Of Property, Plant And Equipment (detail)
Related Party Transactions
Related Party Transactions - Additional Information (detail)
Schedule Ii - Valuation And Qualifying Accounts
Schedule Ii - Valuation And Qualifying Accounts (detail)
Selected Quarterly Financial Data (unaudited)
Selected Quarterly Financial Data (unaudited) (tables)
Selected Quarterly Financial Data (unaudited) - Schedule Of Quarterly Results Of Operations (unaudited) (detail)
Stock Based Compensation
Stock Based Compensation (tables)
Stock Based Compensation - Additional Information (detail)
Stock Based Compensation - Schedule Of Restricted Stock Activity (detail)
Stock Based Compensation - Schedule Of Stock Option Activity (detail)
Stock Based Compensation - Schedule Of Stock-based Compensation Expense (detail)
Stock Based Compensation - Schedule Of Weighted Average Assumptions Used As Inputs To Black-scholes Option Pricing Model (detail)
Stockholders Equity - Additional Information (detail)
Stockholders' Equity
Subsequent Events
Subsequent Events - Additional Information (detail)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (policies)
Summary Of Significant Accounting Policies (tables)
Summary Of Significant Accounting Policies - Additional Information (details)
Summary Of Significant Accounting Policies - Property, Plant And Equipment, Useful Life (details)
Ticker: ATNX
CIK: 1300699
Form Type: 10-K Annual Report
Accession Number: 0001564590-18-006715
Submitted to the SEC: Mon Mar 26 2018 8:01:55 AM EST
Accepted by the SEC: Mon Mar 26 2018
Period: Sunday, December 31, 2017
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media
SEC.gov

Bookmark the Permalink:
https://last10k.com/sec-filings/atnx/0001564590-18-006715.htm